Some of the available research suggests that the use of metformin [42,55,56], thiazolidinediones and GLP-1 receptor agonists [57,58,59,60], or DPP4 inhibitors [60,61,62] may reduce the risk of developing PD in people with T2DM. Here, DPP4 is linked to Parkinson disease.